PRODUCTS

Polybrominated Diphenyl Ethers: Structure Determination and Trends in Antibacterial Activity

Hongbing Liu,[†] Katheryn Lohith,[†] Margaret Rosario,[†] Thomas H. Pulliam,[†] Robert D. O'Connor,[†] Lori J. Bell,[‡] and Carole A. Bewley^{*,†}

[†]Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892-0820, United States

[‡]Coral Reef Research Foundation, Koror, PW 96940, Palau

S Supporting Information

ABSTRACT: Antibacterial-guided fractionation of the Dictyoceratid sponges *Lamellodysidea* sp. and two samples of *Dysidea granulosa* yielded 14 polybrominated, diphenyl ethers including one new methoxy-containing compound (8). Their structures were elucidated by interpretation of spectroscopic data of the natural product and their methoxy derivatives. Most of the compounds showed strong antimicrobial activity with low- to sub-microgram mL⁻¹ minimum inhibitory concentrations against drug-susceptible and drug-resistant strains of *Staphylococcus aureus* and *Enterococcus faecium*, and two compounds inhibited *Escherichia coli* in a structure-dependent manner.



Marine sponges of the Dysideidae family are known for containing a rich array of diverse natural products. Examples include unusual sterols, ^{5–7} glycolipids, ⁸ sesterterpenes, ⁹ and sesquiterpene quinones; ¹⁰ the peptidic natural products dysinosins, ^{11,12} dysideaprolines, and barbaleucamides; ¹³ and numerous polybrominated and hydroxylated diphenyl ethers (PBDEs). ^{14–17} Halogenated diphenyl ethers in general have garnered attention from different fields. Revealed by natural products chemists, they represent some of the earliest discoveries of polyhalogenated compounds coming from nature. ¹⁸ The distribution of synthetic polychlorinated and polybrominated biphenyls continues to be studied by environmental toxicologists. ^{19,20} Most recently Agarwal et al. described a biosynthetic scheme that can lead to formation of PBDEs in a



widespread marine bacterium.²¹ In addition to isolating known PBDEs 1-7 from *D. granulosa* and *Lamellodysidea* sp., we describe the structural assignment of a new PBDE, compound 8 (Figure 1), along with an approach to assign bromination and hydroxylation patterns in substituted diphenyl ethers. Unexpected trends in antibacterial activities were observed for these compounds.

The extracts of Lamellodysidea sp. and two collections of D. granulosa inhibited the growth of both Gram-positive and Gram-negative bacteria. The Gram-positive bacteria included Bacillus subtilis and drug-susceptible and drug-resistant strains of Staphylococcus aureus and Enterococcus faecium, with E. coli representing Gram-negative bacteria. With an emphasis on identifying the compounds responsible for the Gram-negative inhibitory activity, we fractionated these extracts on HP20SS eluting with H₂O to MeOH followed by acetone. LC-MS and NMR analyses of the E. coli-active fractions identified a number of known PBDEs, along with a new compound, 8. Compound 8 was isolated as a white solid, and the low-resolution ESIMS spectrum of 8 showed a distribution of negatively charged ions at m/z 620.6, 622.6, 624.6, 626.6, 628.6, and 630.6 having relative intensities of 1:4:6:6:4:1, which indicated the presence of five bromine atoms in the molecule. The molecular formula of C13H7Br5O4 was determined by HRESIMS, indicating eight degrees of unsaturation.

Received: March 13, 2016



This article not subject to U.S. Copyright. Published XXXX by the American Chemical Society



Figure 1. Compounds isolated from Lamellodysidea sp. (1-8), two collections of Dysidea granulosa (9-14), synthetic methylates 3a-6a and 8a, and a commercial 2,2'-dihydroxydiphenyl ether (15).

Table 1. ¹H (500 MHz) and ¹³C NMR (126 MHz) Data for 8 and 8a^a

	8				
position	$\delta_{ m C}$, type	$\delta_{ m H}$ (J in Hz)	$\delta_{ m C'}$ type	$\delta_{\rm H}$ (J in Hz)	$\Delta \delta_{\rm C} (\delta_{8 \rm a} - \delta_8)$
1	144.9, C		150.8, C		5.9
2	142.7, C		145.5, C		2.8
3	111.3, C		119.2, C		7.9
4	116.3, CH	7.37, d (2.2)	116.9, CH	7.40, d (2.2)	0.6
5	111.8, C		116.8, C		5.0
6	129.5, CH	6.54, d (2.2)	129.4, CH	6.49, d (2.2)	-0.1
1'	145.1, C		148.5, C		3.4
2'	138.8, C		145.0, C		6.2
3'	119.2, C		119.4, C		0.1
4′	149.0, C		152.6, C		3.6
5'	113.4, C		113.5, C		0.2
6'	114.2, C		121.7, C		7.5
-OH		7.08, br s			
-OH		7.56, br s			
1'-OCH ₃			61.6, CH ₃	3.79, s	
4'-OCH ₃	61.1, CH ₃	3.87, s	61.0, CH ₃	3.91, s	
2-OCH ₃			61.3, CH ₃	4.00, s	

в

^{*a*}Chemical shifts (δ) are referenced to residual CDCl₃ (¹H: 7.26/¹³C: 77.16 ppm).

The ¹H NMR spectroscopic data of compound 8 (Table 1) exhibited a pair of meta-coupled (2.2 Hz) signals at $\delta_{\rm H}$ 6.54 and 7.37 and one methoxy group at $\delta_{\rm H}$ 3.87 (s, 3H). Two broad singlets ($\delta_{\rm H}$ 7.08 and 7.56) in the ¹H NMR spectrum were tentatively assigned as hydroxy groups. The presence of one methoxy carbon, two sp² methines, and 10 sp² nonprotonated carbons was apparent from the ¹³C NMR and HSQC spectra, consistent with 8 being a polybrominated diphenyl ether.²² Methylation of 8 to give 8a confirmed the presence of two hydroxy groups (Table 1).

The locations of the bromines and hydroxy groups in ring A of 8 and 8a were clear from the chemical shifts, meta-coupling, and HMBC correlations. The HMBC spectra (Figure 2) showed couplings from H-4 to C-2, C-3, C-5, and C-6 and from H-6 to C-1, C-2, C-4, and C-5 in 8 and 8a. Additionally, the coupling from the methoxy group at $\delta_{\rm H}$ 4.00 to C-2 in derivative 8a established the positions of the ether and hydroxy groups in ring A and the chemical shifts of C-1 and C-2. These data indicated that the meta-coupled protons were para to the



Figure 2. HMBC correlations used in structure determination of compounds 8 and 8a.

ether and to a brominated carbon, leaving only the H-4/H-6 arrangement possible.

Assignment of the substitution pattern in ring B was more challenging due to the lack of HMBC correlations. In addition, the ¹³C chemical shifts did not match any known PBDEs. This was likely due to the presence of a methoxy group that affects ¹³C chemical shifts in PBDEs.²³ We tentatively assigned the position of the naturally occurring $-OCH_3$ group in ring B using a combination of NOEs and distance comparisons from molecular modeling. In selective 1D-NOE spectra of **8** an NOE

DOI: 10.1021/acs.jnatprod.6b00229 J. Nat. Prod. XXXX, XXX, XXX–XXX between the OCH_3 and H-6 was the only one observed (Figure S13, Supporting Information). As shown in Figure 3, this



Figure 3. Interproton distances of three possible isomers of 8 and NOEs observed for 8a. Coordinates for the three possible structures of compound 8 were energy minimized using Chem3D, and interproton distances between H-4 and H-6 of ring A and the $-OCH_3$ group in ring B were measured in each and compared to the experimental NOE data (A–C). The isomer shown in B (1'-hydroxy-3'-methyoxy) predicts NOEs that are not observed, and the isomer in C (1'-hydroxy-5'-methyoxy) shows a distance greater than 5.5 Å for an NOE that is present. Panel D shows the NOEs observed for methylated 8a, in agreement with experimental data. 1D NOE spectra are shown in Figure S13.

suggests that the $-OCH_3$ group is located *meta* to the ether and attached at C-4' or C-6'. In the NOE spectra of methylated derivative **8a**, NOEs between the new methoxy group in ring B and H-6 and $-OCH_3$ in ring A were present (Figure 3D); however no NOEs were observed between the two $-OCH_3$ groups in ring B (Supporting Information). This suggested that the hydroxy group in **8** was *para* to the $-OCH_3$ group and thus located at C-1'.

To provide additional support for the location of substituents in ring B of compound 8, we prepared the methoxy derivatives of known compounds 3-6 by treatment with iodomethane to give compounds 3a-6a, with 3a and 5a being new compounds (Supporting Information), and compared their ¹³C chemical shifts. Compared to the parent compounds 3-6, chemical shifts for C-1, C-3, and C-5 in ring A and C-2', C-4', and C-6' in ring B were deshielded by an average of 6.4, 8.3, 4.6, 4.7, 3.2, and 4.0 ppm, respectively. Similarly, the corresponding carbons in 8 and 8a were deshielded by 5.9, 7.9, 5.0, 6.2, 3.6, and 7.5 ppm (Table 1). These trends in chemical shifts are consistent with the substitution pattern suggested above and confirm the locations of the bromine, hydroxy, and methoxy substituents. We note that these chemical shift changes at positions ortho and para to a methoxy group are seen at both protonated and halogenated carbons, making this a useful approach for assigning these complex substitution patterns. Interestingly, compounds originating from Lamellodysidea all contained a 2hydroxy-3,5-dibromophenyl moiety for ring A, while compounds from D. granulosa uniformly contained a 2,4dibromophenyl moiety, making this chemistry specific for taxonomically distinct marine sponge samples (Table 2).

Table 2. Occurrence of Compounds in Three DysideaeSponges

sponge	NPID number ^a	collection site	compounds	
Lamellodysidea sp.	C024121	Papua New Guinea	1-8	
Dysidea granulosa	C031381	Palau	9-13	
Dysidea granulosa	C024075	Papua New Guinea	9, 10, and 14	
^a Corresponds to number.	the NCI Open	Repository Natural	Products ID	

We tested compounds 1–14 for antibacterial activities against the panel of drug-susceptible and drug-resistant bacteria and fungi shown in Table 3. Compounds 2–13 showed strong antibacterial effects toward *S. aureus* and *E. faecium* strains, exceeding the potency of control antibiotics oxacillin and vancomycin. Surprisingly and unlike the other compounds, 9 and 11 also inhibited the growth of *E. coli* with MICs of 3.1 and 12.5 μ g/mL, respectively. Though previously reported to have broad-spectrum antibacterial activity²⁴ in our antimicrobial assays, compound 10 did not inhibit the growth of *E. coli*. None of the compounds were active against *P. aeruginosa* or *C. albicans*.

Compounds 1-14, 3a-6a, and 8a were tested for cytotoxicity against a monkey kidney cell line (BSC-1) and a human colorectal tumor cell line (HCT-116).²⁵ Compounds 1-8, 3a-6a, and 8a were nontoxic at the maximum tested concentration (50 μ g/mL). Compounds 9–14 showed some toxicity against the kidney cell line BSC-1 with IC₅₀'s between 7 and 35 μ g/mL. Although their ring B structures are similar, rings A of compounds 9-14 lack a hydroxy and contain bromine atoms ortho and para to the ether compared to compounds 2-8. This difference in conjunction with the cellbased screens suggests that the lack of the hydroxy group on ring A and/or the bromine substitution pattern leads to increased cytotoxicity. To explore whether halogens are required for these activities, we tested the commercially available compound 2,2'-dihydroxydiphenyl ether (15) for cytotoxity and antibacterial activity; it was inactive in all assays, as were the permethylated derivatives 3a-6a and 8a. The observed structure-activity relationship suggests that ring B needs two bromine atoms and a C-1' hydroxy group for antibacterial activity. Further, the presence of two phenolic hydroxy groups at C-1' and C-2 in PBDEs decreases cytotoxity, but also corresponds to a loss in activity against the Gramnegative bacterium E. coli.

In summary, we isolated 14 polybrominated and hydroxylated diphenyl ethers from related Dysideidae sponges and demonstrated a simple method employing methylation and associated changes in ¹³C chemical shifts to assign complex substitution patterns in proton-deficient structures. Because it can be used on compounds of this class that contain both hydroxy and methoxy substitutents, this method augments previous NMR approaches that have been used in PBDE analyses.²³ Although superficially compounds 1-14 appear to be highly similar to one another, their antibacterial spectrum and potencies, as well as cellular cytotoxicities, differed greatly as a function of the presence and pattern of hydroxy and bromine substituents. Given the difficulty of identifying small molecules that inhibit the growth of Gram-negative organisms, these results may provide insights into features that lead to this activity.

Table 3. Minimum Inhibito	ry Concentrations and C	cytotoxicity of Com	154 npounds 1–14, 3a–6a, 8a, and
---------------------------	-------------------------	---------------------	----------------------------------

	S. aureus ATCC 29213	S. aureus ATCC 43300	E. faecium ATCC 29212	E. faecium ATCC 51299	E. coli ATCC 25922	P. aeruginosa ATCC 27853	C. albicans ATCC 28517	Bsc-1
1	100	>50	12.5	25	>100	>50	>50	>50
2	1.6	1.25	3.1	1.6	50	>50	>50	>50
3	1.6	0.31	3.1	3.1	100	>50	>50	>50
4	0.78	0.16	1.6	0.78	50	>50	>50	>50
5	0.31	0.16	1.6	0.78	50	50	>50	>50
6	0.31	0.078	0.39	0.39	25	50	>50	>50
7	0.39	0.16	0.78	0.39	50	50	50	>50
8	0.78	0.39	3.1	1.56	>50	>50	>50	>50
3a	>50	>50	50	>50	>50	>50	>50	>50
4a	>50	>50	50	50	>50	>50	>50	>50
5a	>50	>50	>50	>50	>50	>50	>50	>50
6a	>50	>50	>50	>50	>50	>50	>50	>50
8a	3.1	3.1	13	13	>50	>50	>50	>50
9	0.042	0.08	1.2	1.2	3.1	>50	>50	7.0
10	0.78	0.19	0.8	0.8	>100			32
11	0.14	0.015	0.4	0.4	12.5			8.8
12	3.7	0.4	1.2	1.2	>100			15
13	1.6	0.8	33	33	>100			29
14	3.7	0.4	11	11	>100			35
15	50	50	>50	>50				
oxacillin	0.13	>32		32				
gentamicin					0.5	1		
vancomycin		1	2					
amphotericin B							<7.8	
^a MICs and cyto	toxity data are re	ported in <i>ug/</i> mI	4.					

EXPERIMENTAL SECTION

General Experimental Procedures. UV–vis spectra were recorded on an Agilent 8453 spectrophotometer, and IR spectra on a PerkinElmer Frontier FT-IR spectrophotometer (KBr). NMR spectra were recorded at 298 K on a Bruker Avance500 spectrometer equipped with a triple resonance cryoprobe and *z* gradients. Transient NOE spectra were acquired with a 1 s mixing time using a selective 1D double pulsed field gradient spin echo pulse program incorporating perfect-echo excitation, alternating gradient polarity, and zero quantum suppression.^{26–29} LRESIMS was carried out on an Agilent 1100 LC system and a 6310 MSD. HRESIMS was carried out on a Waters time-of-flight mass spectrometer model LCT Premier. Semipreparative HPLC (Agilent 1100) was performed using a Waters XBridge preparative C18 column (10 × 250 mm, S-5 μ m, 12 nm). All solvents (HPLC grade) and Diaion HP20SS gel were obtained from Sigma-Aldrich.

Animal Material. Extracts from the three Dysideidae sponge samples used in this study were obtained from the NCI Open Repository. *Lamellodysidea* sp. (NPID no. C024121) was collected at a depth of 43 m in Papua New Guinea in June 2003. *Dysidea granulosa* (NPID no. C024075) was collected in Papua New Guinea at a depth of 10 m, and a separate collection of *D. granulosa* (NPID no. C031381) was collected in June 2010 in the Palau Islands. Taxonomic identifications were made by Michelle Kelly or one of the authors, L.J.B. Voucher specimens are available at the NCI, Frederick, MD, USA, and at the Smithsonian Museum, Washington, DC.

Extraction and Isolation. Organic extracts from the above three sponges were prepared by extraction with MeOH–CH₂Cl₂ and stored at -50 °C until shipment. The organic extract of *Lamellodysidea* sp. (5 g) was chromatographed on a Diaion HP20SS-gel column equilibrated in H₂O and was eluted with a 10% stepwise gradient from H₂O to MeOH. Fractions were combined into three groups, A–C, on the basis of antimicrobial activity. Fraction C (4.5 g) was purified by semipreparative HPLC (5 mL/min, 0–15 min, 50–85%; 15–40 min 85–95% MeCN–H₂O gradient elution) to yield compounds 1 (0.4 mg, $t_{\rm R}$ 14.5 min), 2 (1.1 mg, $t_{\rm R}$ 24.0 min), 8 (3.3 mg, $t_{\rm R}$ 24.5 min), a mixture of compounds with a $t_{\rm B}$ of 27 min, 4 (10 mg, $t_{\rm R}$ 27.5 min), 5

(4.2 mg, $t_{\rm R}$ 29.5 min), and 7 (114 mg, $t_{\rm R}$ 31.0 min). The mixture eluting at 27 min was resubjected to semipreparative HPLC (5 mL/min, 30 min, 50–70% MeCN–H₂O gradient elution) to give compounds 6 (6.4 mg, $t_{\rm R}$ 23.5 min) and 3 (15 mg, $t_{\rm R}$ 25.0 min).

The organic extract (2.19 g) of *D. granulosa* (NPID no. C031381) was dissolved in MeOH and chromatographed on a Diaion HP20SSgel column eluting with water to MeOH, followed by acetone, to give seven fractions (A–G), which were combined on the basis of their LC-MS profiles. The acetone fraction G (1.44 g) was subjected to reversed-phase HPLC (XBridge prep, Waters C18, 5 μ m) eluting with a linear gradient of 0.1% TFA in H₂O and 0.05% TFA in MeCN (60– 100% in 40 min, flow rate 5 mL/min) to yield compounds 9 (38 mg, t_R 14.5 min), **10** (1.2 mg, t_R 17.3 min), **11** (38.6 mg, t_R 18.0 min), **12** (13.4 mg, t_R 19.0 min), and **13** (1.7 mg, t_R 22.7 min).

The organic extract (2 g) of *D. granulosa* (NPID no. C024075) was dissolved in MeOH and chromatographed on a Diaion HP20SS-gel column as described above. The acetone fraction G (0.35 g) was subjected to reversed-phase HPLC (5 mL/min, 60–80% H₂O–MeCN with 0.01% TFA, gradient elution in 40 min) to yield compounds **9** (20.2 mg, $t_{\rm R}$ 18.5 min), **10** (6.0 mg, $t_{\rm R}$ 18.5 min), and **14** (2.1 mg, $t_{\rm R}$ 37.5 min).

1-(3',5',6'-Tribromo-4'-methoxy-1'-hydroxyphenoxy)-3,5-dibromo-2-phenol (**8**): white solid; UV (MeOH) λ_{max} (log ε) 213 (5.64), 297 (4.57) nm; IR (film) ν_{max} 2918, 2865, 1711, 1415, 1234 cm⁻¹; ¹H and ¹³C NMR data, Table 1; LRESIMS *m*/*z* 620.6 [M - H]⁻; HRESIMS *m*/*z* 620.6187 [M - H]⁻ (calcd for C₁₃H₆Br₅O₄, 620.6183).

1-(3',4',6'-Tribromo-1'-methoxyphenoxy)-3,5-dibromo-2methoxybenzene (**3a**): white solid; UV (MeOH) λ_{max} (log ε) 214 (5.12) nm; IR (film) ν_{max} 2917, 2864, 1701, 1413, 1232 cm⁻¹; ¹H and ¹³C NMR data, Supporting Information; HRESIMS *m*/*z* 619.6458 [M + H]⁺ (calcd for C₁₄H₉Br₅O₃, 619.6468).

1-(4',5',6'-Tribromo-1'-methoxyphenoxy)-3,5-dibromo-2methoxybenzene (**5a**): white solid; UV (MeOH) λ_{max} (log ε) 216 (5.34) nm; IR (film) ν_{max} 2917, 2865, 1701, 1510, 1493, 1482 cm⁻¹; ¹H and ¹³C NMR data, Supporting Information; HRESIMS *m*/*z* 619.6473 [M + H]⁺ (calcd for C₁₄H₉Br₅O₃, 619.6468). 1-(3',5',6'-Tribromo-1',4'-dimethoxy-1'-phenoxy)-3,5-dibromo-2-methoxybenzene (**8a**): UV (MeOH) λ_{max} (log ε) 214 (5.68), 295 (4.44) nm; IR (film) ν_{max} 2917, 2865, 1711, 1415, 1234 cm⁻¹; ¹H and ¹³C NMR data, Table 1; HRESIMS *m*/*z* 649.6567 [M + H]⁺ (calcd for C₁₅H₁₁Br₅O₄, 649.6574).

Methylation of Compounds 3–6 and 8. Compound 3 (2.0 mg, 3 μ mol) was added to a solution of acetone (500 μ L) in the presence of K₂CO₃ (0.1 mg) and MeI (400 μ L, 6 μ M) at rt. The solution was stirred for 1 h, dried under a stream of N₂, and extracted with CHCl₃ to give **3a** as a white solid (2.3 mg, 100%). By the same method compounds **4a** (1.7 mg, 95%), **5a** (2.0 mg, 84%), **6a** (3.3 mg, 95%), and **8a** (0.6 mg, 100%) were obtained from **4** (1.5 mg), **5** (2.0 mg), **6** (3.0 mg), and **8** (0.5 mg), respectively.

MIC and Cytotoxicity Determination. MICs were determined by testing all compounds in duplicate in at least two independent experiments for their antimicrobial activity against laboratory strains listed in Table 3 and as described in the Clinical and Laboratory Standards Institute (CLSI) guidelines.³⁰ All laboratory bacterial strains were obtained from the American Type Culture Collection. Experimental details for MIC and cytotoxicity data are provided in the Supporting Information.

ASSOCIATED CONTENT

S Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.jnat-prod.6b00229.

IR, HRMS, and ¹H, ¹³C, and 2D NMR spectra of new compounds and protocols for biological testing (PDF)

AUTHOR INFORMATION

Corresponding Author

*Tel: +1-(301)-594-5187. E-mail: caroleb@mail.nih.gov.

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

We thank J. Lloyd for HRMS data and the NCI Open Repository for organic extracts. This work was supported by the NIH Intramural Research Program (NIDDK). T.P. acknowledges a Park Scholarship.

REFERENCES

(1) Walsh, C. Antibiotics: Actions, Origins, Resistance, 1st ed.; ASM Press: Washington, DC, 2003.

(2) Payne, D. J.; Gwynn, M. N.; Holmes, D. J.; Pompliano, D. L. Nat. Rev. Drug Discovery **2007**, *6*, 29–40.

- (3) Silver, L. L. Expert Opin. Drug Discovery 2008, 3, 487-500.
- (4) Silver, L. L. Future Microbiol. 2015, 20, 1711-1718.

(5) Boonlarppradab, C.; Faulkner, D. J. J. Nat. Prod. 2007, 70, 846–848.

(6) De Almeida Leone, P.; Redburn, J.; Hooper, J. N. A.; Quinn, R. J. J. Nat. Prod. **2000**, 63, 694–697.

(7) Milkova, T. S.; Mikhova, B. P.; Nikolov, N. M.; Popov, S. S.; Andreev, S. N. J. Nat. Prod. **1992**, 55, 974–978.

(8) Costantino, V.; Fattorusso, E.; Imperatore, C.; Mangoni, A. J. Nat. Prod. 2002, 65, 883–886.

(9) Kernan, M. R.; Cambie, R. C.; Bergquist, P. R. J. Nat. Prod. 1991, 54, 265–268.

(10) Du, L.; Zhou, Y. D.; Nagle, D. G. J. Nat. Prod. 2013, 76, 1175–1181.

(11) Carroll, A. R.; Buchanan, M. S.; Edser, A.; Hyde, E.; Simpson, M.; Quinn, R. J. *J. Nat. Prod.* **2004**, *67*, 1291–1294.

(12) Carroll, A. R.; Pierens, G. K.; Fechner, G.; De Almeida Leone, P.; Ngo, A.; Simpson, M.; Hyde, E.; Hooper, J. N. a.; Boström, S. L.; Musil, D.; Quinn, R. J. J. Am. Chem. Soc. **2002**, *124*, 13340–13341.

(13) Harrigan, G. G.; Goetz, G. H.; Luesch, H.; Yang, S.; Likos, J. J. Nat. Prod. **2001**, *64*, 1133–1138.

(14) Carté, B.; Faulkner, D. J. Tetrahedron 1981, 37, 2335–2339.

(15) Norton, R. S.; Croft, K. D.; Wells, R. J. Tetrahedron 1981, 37, 2341–2349.

(16) Sharma, G. M.; Vig, B. *Tetrahedron Lett.* **1972**, *13*, 1715–1718.
(17) Agarwal, V.; Li, J.; Rahman, I.; Borgen, M.; Aluwihare, L. I.; Biggs, J. S.; Paul, V. J.; Moore, B. S. *Environ. Sci. Technol.* **2015**, *49*, 1339–1346.

(18) Faulkner, D. J. Nat. Prod. Rep. 1984, 1, 551-598.

(19) Malmvärn, A.; Marsh, G.; Kautsky, L.; Athanasiadou, M.; Bergman, Å.; Asplund, L. *Environ. Sci. Technol.* **2005**, 39, 2990–2997.

(20) Wang, H. S.; Chen, Z. J.; Ho, K. L.; Ge, L. C.; Du, J.; Lam, M. H. W.; Giesy, J. P.; Wong, M. H.; Wong, C. K. C. *Environ. Int.* **2012**, 47, 66–72.

(21) Agarwal, V.; El Gamal, A. a.; Yamanaka, K.; Poth, D.; Kersten, R. D.; Schorn, M.; Allen, E. E.; Moore, B. S. *Nat. Chem. Biol.* **2014**, *10*, 640–647.

(22) Hanif, N.; Tanaka, J.; Setiawan, A.; Trianto, A.; De Voogd, N. J.; Murni, A.; Tanaka, C.; Higa, T. J. Nat. Prod. **2007**, *70*, 432–435.

(23) Calcul, L.; Chow, R.; Oliver, A. G.; Tenney, K.; White, K. N.; Wood, A. W.; Fiorilla, C.; Crews, P. J. Nat. Prod. **2009**, 72, 443–449.

(24) Shridhar, D. M.; Mahajan, G. B.; Kamat, V. P.; Naik, C. G.; Parab, R. R.; Thakur, N. R.; Mishra, P. D. Mar. Drugs **2009**, 7, 464– 471.

(25) Alley, M. C.; Scudiero, D. a.; Monks, A.; Assay, M. T.; Scudiere, D. a.; Hursey, M. L.; Czerwinski, M. J.; Fine, D. L.; Abbott, B. J.; Mayo, J. G.; Shoemaker, R. H.; Boyd, M. R. *Cancer Res.* **1988**, *48*, 589–601.

(26) Stott, K.; Keeler, J.; Van, Q. N.; Shaka, A. J. J. Magn. Reson. 1997, 125, 302-324.

(27) Takegoshi, K.; Ogura, K.; Hikichi, K. J. Magn. Reson. 1989, 84, 611–615.

(28) Thrippleton, M. J.; Keeler, J. Angew. Chem., Int. Ed. 2003, 42, 3938-3941.

(29) Butts, C. P.; Jones, C. R.; Towers, E. C.; Flynn, J. L.; Appleby, L.; Barron, N. J. Org. Biomol. Chem. **2011**, *9*, 177.

(30) CLSI. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard-ninth ed. CLSI document M07-A9; CLSI: Wayne, PA, 2012; Vol. M07-A9.